Skip to main content

Advertisement

Fig. 5 | BMC Cancer

Fig. 5

From: Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST

Fig. 5

Patient with clival chordoma who seems to be experiencing clinical benefit from treatment. a At the most recent follow-up, volume is trending toward improvement (–32.4 %), whereas RECIST measurements have barely changed (+5.0 %). b The patient’s primary lesion. c Twenty-two months later, the patient’s RECIST measurement had not changed. The tumor was smaller by volume but had not yet reached a partial response by volumetric criteria

Back to article page